You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR DESFERAL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DESFERAL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004982 ↗ Combination Iron Chelation Therapy Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 1 1998-12-01 Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. If both drugs can be given orally, there may be a better chance of finding a suitable alternative to Desferal. Several combinations of experimental iron chelating drugs are being used in this trial.
NCT00110266 ↗ Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients Completed Novartis Pharmaceuticals Phase 2 2005-07-25 The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
NCT00293098 ↗ Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease Approved for marketing ApoPharma 2006-03-01 Patients who have iron overload due to chronic blood transfusions and have developed heart failure or who are at high risk of heart failure because of the high levels of iron in their hearts, will be treated with deferiprone, an investigational drug, in combination with deferoxamine (Desferal). Some studies suggest that deferiprone may be better than deferoxamine in removing iron from the heart and improving heart function, and that using both drugs together may remove more iron. Participants would make a clinic visit for lab studies each week, and would continue to take deferiprone for as long as their physician feels it is useful in their care.
NCT00293098 ↗ Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease Approved for marketing Children's Hospital of Philadelphia 2006-03-01 Patients who have iron overload due to chronic blood transfusions and have developed heart failure or who are at high risk of heart failure because of the high levels of iron in their hearts, will be treated with deferiprone, an investigational drug, in combination with deferoxamine (Desferal). Some studies suggest that deferiprone may be better than deferoxamine in removing iron from the heart and improving heart function, and that using both drugs together may remove more iron. Participants would make a clinic visit for lab studies each week, and would continue to take deferiprone for as long as their physician feels it is useful in their care.
NCT00349453 ↗ Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients Completed Lipomed Phase 2 2005-03-01 Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine
NCT00350662 ↗ Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Completed Lipomed Phase 3 2002-01-01 Comparison of efficacy and toxicity of the combination treatment of deferiprone and desferrioxamine with the single agent treatment of either drug
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DESFERAL

Condition Name

Condition Name for DESFERAL
Intervention Trials
Iron Overload 6
Thalassemia 4
Hemochromatosis 2
Myelodysplastic Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DESFERAL
Intervention Trials
Iron Overload 9
Thalassemia 8
beta-Thalassemia 3
Hemochromatosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DESFERAL

Trials by Country

Trials by Country for DESFERAL
Location Trials
United States 38
Switzerland 6
Egypt 3
Canada 3
Iran, Islamic Republic of 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DESFERAL
Location Trials
Massachusetts 3
New York 3
Pennsylvania 2
Michigan 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DESFERAL

Clinical Trial Phase

Clinical Trial Phase for DESFERAL
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DESFERAL
Clinical Trial Phase Trials
Completed 8
Unknown status 3
Not yet recruiting 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DESFERAL

Sponsor Name

Sponsor Name for DESFERAL
Sponsor Trials
Lipomed 2
Ain Shams University 2
Karolinska University Hospital 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DESFERAL
Sponsor Trials
Other 22
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.